Colorectal cancer crc is the third most frequent cancer worldwide and a common cause of cancer death primarily due to metastases that are resistant to conventional therapy. Therapies ciblees et immunomodulation dans les tumeurs. Targeted therapy drugs for colorectal cancer as researchers have learned more about the gene and protein changes in cells that cause colorectal cancer, they have developed newer drugs to specifically target these changes. As of july 1st 2010, only records submitted with full text will be accepted in the academic bibliography. Facteurs predictifs defficacite des therapies ciblees. The underlying biological rationale has been recently elucidated. Cyp2d6 for tamoxifen in breast cancer, kras for anti egfr antibodies in colorectal cancer, and bcrabl1 for tyrosine kinase inhibitors in chronic myeloid leukemia. Five advanced pancreatic cancer patients in a phase i study.
Due to the known expression of egfr in colorectal cancer, a phase ii trial of cetuximab, an antiegfr monoclonal antibody, in patients with refractory egfrpositive assessed by immunohistochemistry colorectal cancer. Antiepidermal growthfactor receptors do not benefit colorectal cancer patients with kras mutations. Use of antiegfr antibodies cetuximab and panitumumab in the treatment of metastatic colorectal cancer in kras wild type patients volume 96, special issue 4, decembre 2009 pdf print. The rationale for antiegfr therapies in cancer treatment relies on the role that egfr may play in tumorigenesis and the frequent overexpression or hyperactivation of egfr noted in many tumor types, including colorectal cancer crc, squamous cell carcinoma of the head and neck scchn, and nonsmallcell lung cancer.
Optimising the use of cetuximab in the continuum of care. External quality assessment unravels interlaboratory differences in. Emergence of kras mutations and acquired resistance to antiegfr therapy in colorectal cancer. Clinical relevance of egfr and krasstatus in colorectal. Jun, 2012 molecular alterations in kras are associated with acquired resistance to anti epidermal growth factor receptor egfr treatment in colorectal cancer. Relationship between 18ffdg petct scans and kras mutations. Colorectal cancer predictive testing for antiegfr therapy indications for ordering indicated for individuals with metastatic colorectal cancer crc to guide treatment with antiegfr monoclonal. Pdf monoclonal antiegfr antibodies in the treatment of. A total of 75 colorectal cancer outpatients treated with an antiegfr antibody combined with folfox, folfiri, or 5fuleucovorin as the first to. However, only a small percentage of unselected patients around 10% are responsive to these costly agents. The current standard of care for resectable liverlimited colorectal cancer is perioperative chemotherapy followed by curative resection, based on the eortc trial, which showed a modest improvement in 3. Furthermore, obesity may decrease the effectiveness of anti. Performance and cost e ciency of kras mutation testing for. However, there is evidence that adding these agents to standard chemotherapy might be detrimental.
Pdf primary and acquired resistance of colorectal cancer. Mechanisms of resistance to antiegfr therapy in colorectal cancer article pdf available in oncotarget 83 july 2015 with 468 reads how we measure reads. Circulating tumor dna analysis in colorectal cancer. Antiegfr agents and colorectal cancer patients with kras. Kras is a gtpbinding protein which plays a crucial role in. Targeting epidermal growth factor receptor egfr in. Resistance to antiegfr therapy in colorectal cancer.
Pdf mm151 overcomes acquired resistance to cetuximab and. This metaanalysis was performed to determine the optimal use of antiegfr mab in the treatment of metastasized colorectal cancer mcrc. Many studies have therefore assessed their clinical significance as diagnostic and prognostic marker in colorectal cancers. Current status of cetuximab for the treatment of patients.
The results of this trial, reported in 2004, were promising. The discovery that ras mutations could be used to predict sensitivity and resistance to antiepidermal growth factor receptor egfr therapy in patients with colorectal cancer crc has. We present the current treatments of metastatic colorectal cancer, the. This metaanalysis was performed to determine the optimal use of anti egfr mab in the treatment of metastasized colorectal cancer mcrc. Performance and cost efficiency of kras mutation testing for. Cetuximab and panitumumab, monoclonal antibodies used to target the epidermal growth factor receptor egfr, were recently approved by the united states food and drug administration for use as single agents or in combination with other chemotherapy drugs in the treatment of metastatic colorectal cancer. Kras testing for antiegfr therapy in advanced colorectal. Patients with colorectal cancer 6, lapc 3, and mpc 2 were treated with egfr bats after 1 cycle of folfox6 oxaliplatin and leucovorin, 5 fu given to create immune space. Amplification of the met receptor drives resistance to antiegfr therapies in colorectal cancer. Molecular alterations in kras are associated with acquired resistance to antiepidermal growth factor receptor egfr treatment in colorectal cancer. Consider clinical trials as treatment options for eligible patients. Antiegfr therapy in rightsided metastatic colorectal. External quality assessment unravels interlaboratory. As per the law relating to information storage and personal integrity, you have the right to oppose art 26 of that law, access art 34 of that law and rectify art 36 of that law your personal data.
Primary and acquired resistance of colorectal cancer cells to anti egfr antibodies converge on mekerk pathway activation and can be overcome by combined mekegfr inhibition. Emergence of kras mutations and acquired resistance to. Oct 09, 2009 antiepidermal growthfactor receptors do not benefit colorectal cancer patients with kras mutations. Bacteria may be the missing link accounting for the different tumor biology of the right colon that leads to resistance to antiegfr therapy. This work highlights how tissuebased and liquid biopsy can reveal the intralesion and interlesion molecular landscape that emerges in patients with colorectal cancer. A european external quality assessment scheme monitored the performance of laboratories and evaluated the. However, there is evidence that adding these agents to standard chemotherapy might be. This work highlights how tissuebased and liquid biopsy can reveal the intralesion and interlesion molecular landscape that emerges in patients with colorectal cancer treated with panitumumab and cetuximab. The antiepidermal growth factor receptor antibody antiegfr cetuximab has been proven to be efficient in metastatic colorectal cancer. Evolution during antiegfr treatment in colorectal cancer highlights d nf1 and noncanonical kras and braf aberrations associate with cetuximab resistance d genetic resistance drivers are absent in most.
For now, the right colon is probably the wrong place to consider using singleagent cetuximab or panitumumab. The antiepidermal growth factor receptor egfr antibodies cetuximab and. Egfr antibodies in resectable metastatic colorectal liver. Antiegfr retreatment has been studied in patients with metastatic colorectal cancer. Activation of signal pathways and the resistance to anti. Subanalyses of the crystal and fire3 trials showed a clear benefit in metastatic colorectal cancer mcrc patients with leftsided tumors l but limited benefit in patients with right. A new microarray substrate for ultrasensitive genotyping of kras and braf gene variants in colorectal cancer. Currently, the best predictor of efficacy is the absence of mutations in kras and nras genes. Regulations for the selection of patients with metastatic colorectal cancer for anti. A rational twostep approach to kras mutation testing in colorectal cancer. No benefit from the addition of antiegfr antibody in all. Primary and acquired resistance of colorectal cancer cells to antiegfr antibodies converge on mekerk pathway activation and can be overcome by combined mekegfr inhibition. Chemotherapy with or without antiegfr agents in left and.
Les anticorps antiegfr, cetuximab en tete et, plus recemment, le panitumumab, constituent une avancee indeniable dans le traitement du cancer colorectal. Her2 amplification and antiegfr sensitivity in advanced. Cancer colorectaux metastatiques et therapies ciblees antiegfr. The major challenge is the identification of patients who would benefit from treatment. From heterogeneity to convergent evolution sandra misale 1,2, federica di nicolantonio 1,2, andrea sartorebianchi 3, salvatore siena 3, and alberto bardelli 1,2,4. Due to the known expression of egfr in colorectal cancer, a phase ii trial of cetuximab, an anti egfr monoclonal antibody, in patients with refractory egfrpositive assessed by immunohistochemistry colorectal cancer was undertaken. Ainsi des homocombinaisons danticorps antiegfr epidermal growth. Colorectal cancer is the fourth most prevalent cancer type in the world and causes nearly 700 000 deaths per year worldwide. Several studies have shown that kras mutations in colorectal cancer crc result in the lack of response to antiepidermal growth factor receptorbased therapy. Cancer colorectal metastatique et therapies ciblees. Treatment with antiegfr monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer.
Optimal use of anti egfr monoclonal antibodies for patients with advanced colorectal cancer. Les biomarqueurs predictifs dans le cancer colorectal revue. Panitumumab and cetuximab bind to egfr extracellular. Efficacy of sym004 in patients with metastatic colorectal. Objective primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. More recently, their location downstream to egfr and kras in the rasmapk pathway have led to their evaluation as predictive marker of resistance to anti egfr monoclonal antibodies.
Kras testing for anti egfr therapy in advanced colorectal cancer. Genomic and transcriptomic determinants of therapy. Metastatic colorectal cancers and targeted therapy against egfr. Regulations for the selection of patients with metastatic colorectal cancer for antiegfr treatment changed at the end of 20. N tests moleculaires et cancer colorectal metastatique chez. The anti epidermal growth factor receptor monoclonal antibodies cetuximab and panitumumab have established efficacy as single agent and in combination with chemotherapy in advanced colorectal cancer. Optimizing treatment with antiegfr monoclonal antibody 903. Targeted therapy drugs for colorectal cancer as researchers have learned more about the gene and protein changes in cells that cause colorectal cancer, they have developed newer drugs to specifically. Sensitivity to antiegfrs epidermal growth factor receptor of metastatic transverse colon.
Emergence of kras mutations and acquired resistance to anti. The purchase of this product conveys to the buyer the nontransferable right to use the purchased product and components of the product only in research conducted by the buyer whether the buyer is an academic or forprofit entity. Dec 01, 2010 terasawa t, dahabreh i, castaldi pj, trikalinos ta. Retreatment with antiegfr monoclonal antibodies in. Pdf optimal use of antiegfr monoclonal antibodies for. Subanalyses of the crystal and fire3 trials showed a clear benefit in metastatic colorectal cancer mcrc patients with leftsided tumors l but limited benefit in patients with rightsided tumors r derived from the addition of cetuximab to firstline chemotherapy. The set of mutations to be tested extended from kras codons. Metastatic colorectal cancer, however, remains an incurable disease. Egfr treatment as it increases the risk factors for colorectal cancer. Seventeen randomized clinical trials were included, all evaluating the added value of anti egfr mab to standard treatment line in patients with kras wildtype mcrc.
Pdf mechanisms of resistance to antiegfr therapy in. Com is registrered at the cnil, declaration n 1286925. Les antiegfr personnalises selon le statut tumoral kras. Antiegfr treatment in patients with colorectal cancer. Alexa fluor r products are provided under an intellectual property license from life technologies corporation.
Many solid tumors overexpress egfr, making it an ideal target for anticancer agents. Kras testing for antiegfr therapy in advanced colorectal cancer. Treatment with anti egfr monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. On the other hand, anti egfr antibodies are used for the treatment of colorectal cancer and head and neck cancer hnc.
Importance acquired resistance to antiegfr therapy epidermal growth factor receptor is frequently due to ras and egfr extracellular domain ecd mutations in metastatic colorectal cancer. Colorectal cancer crc is the third most common malignant disease affecting both men and women in the asiapacific region. Colorectal cancer predictive testing for antiegfr therapy. Initial evaluation should include assessment of family history for hnpcc, fap, or other less common germline mutations associated with colorectal cancer. Kras testing in the selection of colorectal patients for. Over the last couple of years, a series of monoclonal antibodies targeting different tumor cell surface antigens have been tested in both experimental and clinical. John libbey eurotext bulletin du cancer use of antiegfr. The doses of bats in this phase i trial were 10, 20, and 40 x 10 9 batsinfusion given in 3 weekly infusions with a booster infusion at 3 months. From heterogeneity to convergent evolution sandra misale 1,2, federica di nicolantonio 1,2. The set of mutations to be tested extended from kras codons 12 and to kras and nras exons 2, 3, and 4. Without the ras status information, the oncologist can either start chemotherapy with bevacizumab or wait for the introduction of the anti.
458 555 297 16 1450 1301 679 555 220 1355 89 659 376 196 726 578 122 1673 1160 328 1180 340 549 1233 513 184 1174 1115 1350 1482 83 1624 1055 1320 694 1124 676 1248 232 417 296 1361 230 1100 787 837 1289